BRAIN Biotech AG
- WKN: 520394
- ISIN: DE0005203947
- Land: Deutschland
Nachricht vom 15.09.2021 | 21:51
BRAIN Biotech AG successfully placed new share capital for the financing of further growth initiatives
DGAP-News: BRAIN Biotech AG
/ Key word(s): Capital Increase
Zwingenberg, September 15th, 2021
- Around 10% new shares successfully placed
- Approximately EUR 19 million proceeds for growth
The Management Board of BRAIN Biotech AG has, with the approval of the Supervisory Board, successfully completed the issue of approximately 1.99 million new shares (corresponding to approx. 10% of the share capital) as part of a cash capital increase from authorised capital excluding subscription rights.
The new registered shares with no par value were allocated to institutional investors by way of an accelerated bookbuilding process and placed at an issue price of EUR 9.85 per new share. BRAIN's main shareholder participated in the capital increase.
Adriaan Moelker, CEO BRAIN Biotech AG, states: "I like to thank our existing shareholders for their continued support on our innovation path. In addition, I am very happy that we can welcome some new shareholders which have utilized this capital raising as an attractive entry point. The successful placement of new shares is a sign of confidence for us that the capital market supports our business strategy."
"The cash inflow from the capital increase will enable us to accelerate the development of our product pipeline, especially with a focus on the BRAIN Engineered Cas (BEC) technology. In addition, part of the proceeds will be used to finance acquisitions, to further expand our production capacity at Biocatalysts Ltd. and for the purchase of outstanding minority shareholdings in group subsidiaries", added Lukas Linnig, CFO BRAIN Biotech AG.
BRAIN Biotech AG ("BRAIN") is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group. Two pillars form BRAIN Group's business: The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company's own highly innovative products. In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.
Contact Investor Relations
Follow BRAIN Biotech on Twitter (@BRAINbiotech) and on LinkedIn (@BRAIN AG)
|Company:||BRAIN Biotech AG|
|Darmstädter Straße 34-36|
|Phone:||+49 (0) 62 51 / 9331-0|
|Fax:||+49 (0) 62 51 / 9331-11|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1233740|
|End of News||DGAP News Service|
BRAIN Biotech AG: BRAIN and SAMS apply BEC gen ...
BRAIN Biotech AG: Release according to Article ...
BRAIN Biotech AG successfully placed new share ...
BRAIN Biotech AG: BRAIN Biotech AG has success ...
BRAIN Biotech AG resolves on a cash capital in ...
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
30. November 15:26 Neue Sorgen: BioNTech und Moderna geraten unter Druck
30. November 15:30 Buffetts Milliarden-Wette: Nubank-IPO kleiner als erwartet
30. November 16:04 Deutsche Telekom: Droht hier ein neues Problem?
30. November 16:17 Global Fashion Group: Aktie mit Grusel-Chart – gibt es noch Hoffnung?
30. November 16:22 Die Nel-Aktie? Ein Kauf!
News im Fokus
Vonovia SE: Vorstandsmitglieder von Vonovia werden ihre Bezugsrechte ausüben
30. November 2021, 16:02
Capital Markets Day
08. Dezember 2021
Original-Research: clearvise AG (von First Berlin Equity Research GmbH): Buy
30. November 2021